T6278

Sotrastaurin (AEB071) is a potent pan-PKC inhibitor with Kis of 0.95 nM for PKCα, 0.64 nM for PKCβI, 2.1 nM for PKCδ, 3.2 nM for PKCε, 1.8 nM for PKCη, and 0.22 nM for PKCθ.

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral activity, inhibiting the rabies virus (EC50: 1.45 μM) and pseudotyped SARS-CoV-2 (EC50: 14.6 μM).

HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor, with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells, making it useful for AIDS research.

RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 with an IC50 of 51 nM, and also inhibits ALK2 with an IC50 of 5 nM.

KRAS inhibitor-18 (compound 3-10) is a potent inhibitor of KRAS G12C (IC50: 4.74 μM) and exhibited p-ERK inhibition in MIA PaCA-2 and A549 cells with IC50s of 66.4 μM and 11.1 μM, respectively. KRAS inhibitor-18 has potential for pancreatic, colorectal, and lung cancer studies.

KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.

HDAC1-IN-3 is a potent inhibitor of Pf HDAC1, exhibiting a significant in vivo killing effect on all life cycles of the parasite and displaying antimalarial activity in both wild-type and multidrug-resistant strains of the parasite.

GPR52 agonist-1 is a potent, orally active GPR52 agonist that crosses the blood-brain barrier (pEC50:7.53) and has antipsychotic effects. GPR52 agonist-1 significantly inhibited methamphetamine-induced hyperactive behaviour in mice.

Pexidartinib hydrochloride (PLX-3397 HCl) is a selective, orally active, ATP-competitive CSF1R/M-CSFR inhibitor and c-Kit inhibitor with IC50 values of 20 and 10 nM, respectively, capable of inducing cancer cell apoptosis.

Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B bipolar kinase inhibitor with an IC50 of 0.093 μM for Aurora A and 0.09 μM for Aurora B, demonstrating broad-spectrum anti-proliferative activity.